natgillin/translations-raw huggingface dataset:
A composition according to any one of the preceding claims wherein the alkyl sulphate is sodium dodecyl sulphate (SDS), ammonium lauryl sulphate, or sodium laureth sulphate or mixtures thereof. 
Kompozicija prema bilo kojem od prethodnih zahtjeva, naznačeno time da je anionski surfaktant odabran iz perfluoro-oktanoat (PFOA ili PFO), perfluoro-oktan sulfonat (PFOS), natrij dodecil sulfat (SDS), amonij lauril sulfat, i druge alkil sulfatne soli, natrijev lauret sulfata i alkil benzen sulfonat, ili njihove mješavine.
A crystalline form of the compound according to claim 5, wherein the crystalline form has XRPD peaks with a method using Cu anticathode at, at least three of angles: 7.75, 10.13, 17.03, 17.16, 18.39, 21.33, and 21.88. 
Kristalni oblik spoja prema zahtjevu 5, naznačen time da kristalni oblik ima XRPD vrhove uz postupak koji koristi Cu antikatodu kod, barem tri od slijedećih kutova: 7.75, 10.13, 17.03, 17.16, 18.39, 21.33, 121.88.
placing the material inside an interior of a body of an air freshener device, wherein the air freshener device is arranged in such a way as to hold a mobile electronic device; 
stavljanje materijala u nutrašnjost tijela (106) uređaja prema bilo kojem od zahtjeva 1 do 4 ili 7, pri čemu je uređaj raspoređen tako, da drži mobilni elektronički uređaj;
The compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 3, wherein the chemotherapeutic agent is selected from the group consisting of temozolomide, adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, docetaxel, doxorubicin, interferon-alpha, interferon-beta, interferon-gamma, interleukin 2, irinotecan, paclitaxel, topotecan, a taxoid, dactinomycin, danorubicin, 4'-deoxydoxorubicin, bleomycin, pilcamycin, mitomycin, neomycin, gentamycin, etoposide, 4-OH cyclophosphamide, a platinum coordination complex, and mixtures thereof. 
Farmaceutski pripravak prema zahtjevu 6, naznačen time da dodatno sadrži kemoterapijsko sredstvo odabrano iz skupine koja sadrži temozolomid, adriamicin, kamptotecin, karboplatin, cisplatin, daunorubicin, docetaksel, doksorubicin, interferon-alfa, interferon-beta, interferon-gama, interleukin 2, irinotekan, paklitaksel, topotekan, taksoid, daktinomicin, danorubicin, 4'-deoksidoksorubicin, bleomicin, plikamicin, mitomicin, neomicin, gentamicin, etopozid, 4-OH ciklofosfamid, kompleks koordinacije platine, te njihove smjese.
reducing the carbonyl moiety of a lactam of formula IV or formula VII to give the asenapine of formula A; and 
redukciji karbonilnog ostatka u laktamu formule IV ili formule VII kako bi se dobilo asenapin formule A; i
A compound represented by the formula (4): wherein R is a fluorine atom or a methoxy group, and R100 is a C1 - C4 alkyl group, or a salt thereof. 
Spoj, naznačen time što je prikazan formulom (4): [image], gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina, ili njegova sol.
On the one hand, at least one of the enclosure members 9, 13 can be provided with corrugations 21 (s. also figure 8 and corresponding description) which are purposely provided in the front phase of the enclosing member 9. 
S jedne strane, barem jedan od elemenata za obuhvaćanje 9, 13 može imati nabore 21 (vidi također sliku 8 i odgovarajući opis) koji su namjerno stavljeni na prednjoj strani elementa za obuhvaćanje 9.
An example of a linkage as defined herein in depicted in Figure 4. 
Primjer veze kako je ovdje definirana prikazan je na slici 4.
comprising reacting a compound of formula 9: 
[image] reakcijom spoja formule 9:
A nucleic acid comprising a nucleotide sequence encoding a chimeric human/non-human MHC I polypeptide, wherein the nucleotide sequence comprises a first nucleic acid sequence that encodes a1, a2 and a3 domains of a human HLA class I polypeptide and a second nucleic acid sequence that encodes transmembrane and cytoplasmic domains of the non-human MHC I polypeptide such that the nucleotide sequence encodes the chimeric human/non-human MHC I polypeptide. 
PATENTNI ZAHTJEVI Nukleinska kiselina, naznačena time, da obuhvaća nukleotidnu sekvencu koja kodira kimerni ljudski/ne-ljudski MHC-I-polipeptid, pri čemu nukelotidna sekvenca obuhvaća prvu sekvencu nukleinske kiseline koja kodira domene a1, a2, a3 od ljudskog polipeptida HLA razreda I i drugu sekvencu nukleinske kiseline koja kodira transmembranske i citoplazmatske domene ne-ljudskog MHC-I-polipeptida, tako da nukleotidna sekvenca kodira kimerni ljudski/ne-ljudski MHC-I-polipeptid.
or a pharmaceutically acceptable salt or ester thereof. 
ČI ili njegova farmaceutski prihvatljiva sol ili ester.
L is substituted at 3-position or 4-position on the benzene ring of the matrix; wherein one end of atom N is connected with the matrix; 
Lje ili supstituiran na poziciji 3 ili 4 na benzenskom prstenu matrice; pri čemu je jedan kraj atoma N povezan sa matricom;
The polypeptide according to claim 1 consisting of Lip-S5D1-S6D1 (SEQ ID NO: 190). 
Polipeptid sukladno patentnom zahtjevu 1, naznačen time, što se sastoji od Lip-S1D1-S2D1 (SEQ ID NO: 186).
The water was removed by freeze-drying. 
Voda se odstrani liofilizacijom.
The drippable ophthalmic gel according to claim 1, characterized in that the amount of povidone is in the range of >0.8% to 10% by weight. 
Bimatoprost oftalmološki gel u obliku kapi temeljem zahtjeva 1 ili 2, naznačen time da je količina povidona u rasponu od > 0,8 % do 10 % masenog udjela, poželjno > 2,5 % do 10 % masenog udjela.
The compound according to claim 1, wherein the boroarginine moiety comprises a group of the formula: 
Tvar u skladu s patentnim zahtjevom 1, pri čemu boroargininski dio sadrži grupu formule:
is azetidinonyl, pyrrolidinonyl, valerolactamyl, caprolactamyl, maleimido, oxazolidonyl, or dioxothiazinyl, and is substituted with 0-1 substituents selected from the group consisting of hydroxymethyl, acetoxymethyl, and aminomethyl; 
je azetidinonil, pirolidinonil, valerolaktamil, kaprolaktamil, maleimido, oksazolidonil ili dioksoltiazinil, i supstituiran je sa 0-1 supstituentom koji je izabran iz grupe koju čine hidroksimetil, acetoksimetil i aminometil;
Treated animals received IL-2 daily from days 3-10. 
Tretirane životinje primile su dnevno IL-2 od dana 3-10.
A solution for use according to claim 6 or 7, wherein the concentration of the sulfomethylated polymyxin ranges from 70 to 150 mg A/mL, more preferably from 70 to 110 mg A/mL, even more preferably from 70 to 100 mg A/mL. 
Otopina za uporabu sukladno patentnom zahtjevu 7 ili 8, pri čemu je koncentracija sulfometiliziranog polimiksina u rasponu od 90 do 150 mg A/mL.
Aaa is an amino acid residue Thr or Ser; a C-terminus thereof is a free terminus, is amidated or is esterified; 
Aaa je aminokiselinski ostatak, kojeg se bira između Thr i Ser; gdje je njegov C-kraj slobodni kraj, amidiran ili esterificiran;
Method for the control of power fluctuation ramps with energy storage systems in intermittent power generation plants according to claims 1 or 2, characterized in that the substage of setting the dynamic component of the ramp defined as the slope with which the power in the plant is to be varied in each control cycle, according to the state of charge (SOC) of the energy storage system, comprises a stage of filtering dynamic ramps for them not to operate if the plant power is too low or if it is too close to nominal power. 
Postupak kontrole rampi fluktuiranja snage sustavima za pohranu energije u elektranama za intermitentno generiranje snage u skladu s patentnim zahtjevima 1 ili 2, naznačen time što podstadij namještanja dinamične komponente rampe definiran kao nagib pod kojim snaga u elektrani treba varirati u svakom ciklusu kontrole, u skladu sa stanjem napunjenosti (SOC) sustava za pohranu energije, uključuje stadij filtriranja dinamične rampe da elektrane ne rade ako je snaga elektrane preniska ili ako je preblizu nominalnoj snazi.
A method of measuring the levels of an sdAb as claimed in claim 2 in a sample from a subject, the method comprising the steps of: generating a mouse monoclonal antibody directed against one or more domains of a polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:3; performing a quantitative immunoassay on a sample from the subject, wherein the quantitative immunoassay may optionally comprise an enzyme-linked immunosorbent assay (ELISA), specific analyte labeling and recapture assay (SALRA), liquid chromatography, mass spectrometry, fluorescence-activated cell sorting, or a combination thereof, with the mouse monoclonal antibody and the sample to determine the amount of sdAb in a subject; and 
Postupak za mjerenje razine sdAb prema patentnom zahtjevu 2 u uzorku od subjekta, naznačen time što postupak sadrži korake: a) generiranja mišjeg monoklonskog antitijela usmjerenog protiv jedne ili više domena polipeptida koja sadrži aminokiselinsku sekvencu kao što je navedena u SEQ ID NO:3; b) izvođenja kvantitativne imunološke analize na uzorku od subjekta, pri čemu kvantitativna imunološka analiza može izborno sadržavati enzimsku imunoanalizu (ELISA), analizu obilježavanja specifičnog analita i ponovnog hvatanja (SALRA), tekuću kromatografiju, masenu spektrometriju, fluorescencijom-aktivirano sortiranje stanica ili njihovu kombinaciju, sa mišjim monoklonskim antitijelom i uzorkom za određivanje količine sdAb u subjektu; i d) kvantitativno određivanje količine sdAb u subjektu.
The binder composition of claim 7, wherein said catalyst is selected from ammonium para-toluene sulfonate, ammonium naphthalene disulfonate, ammonium sulfate, ammonium chloride, sulfuric acid, lead acetate, sodium acetate, calcium acetate, zinc acetate, organotin compounds, titanium esters, antimony trioxide, germanium salts, sodium hypophosphite, sodium phosphite, methane sulfonic acid and para-toluene sulfonic acid, and mixtures thereof. 
Smjesa veziva prema zahtjevu 15, gdje se katalizator izabire između amonijevog para-toluen sulfonata, amonijevog naftalen disulfonata, amonijevog sulfata, amonijevog klorida, sumporne kiseline, olovo acetata, natrij acetata, kalcij acetata, cink acetata, organotin spojeva, estera titana, trioksida antimona, soli germanija, natrij hipofosfita, natrij fosfita, metan sulfonske kiseline i para tolucn sulfonskc kiseline, i njihovih smjesa.
the composition is for oral administration; and/or 
(a) kompozicija je za oralnu primjenu; i/ili
as a biocidal composition in an aqueous preparation comprising strains of bacteria selected from the group consisting of Methylobacteria and Pseudomonas which are resistant to, tolerant to and/or degrade said aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in absence of lithium ions, wherein the at least one source of a water soluble lithium compound is a polymeric salt of lithium selected from the group consisting of acrylic homopolymers, acrylic copolymers such as copolymers of acrylic acid and maleic acid and/or acrylamide. 
kao biocidni sastav u vodenom pripravku koji sadrži sojeve bakterija odabranih iz skupine koja se sastoji od Methylobacteria i Pseudomonas koji su otporni na, tolerantni na i/ili razgrađuju navedene biocide koji otpuštaju aldehid i/ili biocide s jednom ili više aldehidnih skupina u odsustvu iona litija. Uporaba u skladu s patentnim zahtjevom 15, pri čemu je otopljeni litij u obliku litij iona.
ArylA, ArylB and ArylC are independently aryl which is optionally substituted with a total of from 1 to 8 substituents, wherein: 
ArilA, ArilB i ArilC su nezavisno aril koji je izborno supstituiran sa ukupno od 1 do 8 supstituenata, pri čemu:
inhibition of metastasis of a cell expressing CLDN6. 
(vi) inhibiciju metastaze stanice koja eksprimira CLDN6.
R1a is (a) C1-6 alkyl optionally having 1 to 3 substituents selected from C1-6 alkyl-carbonyloxy, hydroxy and a halogen atom, 
R'*je (a) Crg alkil koji opcijski ima 1 do 3 supstituenta odabrana od sljedećih:
one of the second plurality of impeller blades, 
Datum podnošenja europske prijave patenta:
The demand in the market for such packaging is overwhelming, but the technical challenges even bigger. 
Zahtjev na tržištu za takvo pakiranje je ogroman, a tehnički izazov je još i veći.
The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 8.6, 11.3, 13.1, 15.3, 17.3, 20.5, 22.7, 23.6, 26.3 and 31.4 degrees 2θ. 
Čvrsti oblik u skladu s patentnim zahtjevom 1, naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu s maksimumima na otprilike 8,6, 11,3, 13,1, 15,3, 17,3, 20,5, 22.7, 23,6, 26,3 i 31,4 °2θ.
A process for preparing a compound of formula (1), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group; said process comprising the steps of 
Postupak pripreme spoja sa formulom (1), ili njegove soli, [image] gdje je R1 vodikova ili dušikova zaštitna grupa;
subjecting the co-product stream to a first separation stage to recover a first stream rich in the unfermented organic material and a second stream rich in the protein-containing fermentation agent suspended in water; and 
(iv) podvrgavanje struje ko-proizvoda prvoj fazi odvajanja da se dobije prva struja bogata s nefermentiranim organskim materijalom i druga struja bogata s fermentacijskim sredstvom suspendiranim u vodenoj otopini; i
Use of a composition comprising a GPR119 agonist and a DPP-IV inhibitor for the manufacture of a medicament for the treatment or prevention of a deficiency of GLP-1. 
Uporaba pripravka u skladu sa zahtjevom 1, naznačena time, da se koristi za izradu lijeka za liječenje ili prevenciju nedostatka GLP-1.
The composite panel as claimed in claim 1, wherein said transparent to light material is glass. 
Ploča prema zahtjevu 1, naznačena time što je spomenuti materijal proziran za svijetlost staklo.
Dimethyl fumarate or monomethyl fumarate for use in treating multiple sclerosis, wherein the dimethyl fumarate or monomethyl fumarate is the only neuroprotective compound to be administered, and wherein the dimethyl fumarate or monomethyl fumarate is to be orally administered to a subject in need of treatment for multiple sclerosis at a dose of about 480 mg to about 720 mg per day. 
Dimetil fumarat ili monometil fumarat za upotrebu u liječenju multiple skleroze, naznačen time da je dimetil fumarat ili monometil fumarat jedini neuroprotektivni spoj koji se primjenjuje, i pri čemu se dimetil fumarat ili monometil fumarat oralnim putem daje osobi kojoj je potrebno liječenje multiple skleroze u dozi od 480 mg dnevno.
The glassy solid form of CDDO methyl ester of claim 1, having a Tg value in the range of about 120°C to about 135°C. 
CDDO metilnog estera prema zahtjevu 1 naznačen time da je za uporabu u liječenju kroničnog upalnog stanja kod pacijenata koji pate od istog.
Polydextrose is a polysaccharide composed of glucose units with randomly cross-linked bonds, with 1→6 bonds predominating, containing minor amounts of bound sorbitol and acid. 
Polidekstroza je polisaharid sastavljen od glukoznih jedinica s nasumce raspoređenim poprečnim vezama, pri čemu prevladavaju veze 1>6, te sadržava male količine vezanog sorbitola 1 kiseline.
The antisense oligonucleotide according to claim 1, wherein said antisense oligonucleotide comprises the base sequence of the sequence SEQ ID NO: 5. 
Nekodirajući oligonukleotid sastoji se od slijeda 5' ucagcuucuguuagccacug 3' (SEQ ID NO:5).
The method according to claim 1, wherein the concentration of the basic amino acid or derivative thereof that is sufficient to prevent or reduce aggregation of the Enteroviral particles is maintained throughout the entire duration of at least one of steps (a), (b) and (c). 
Postupak prema bilo kojem od patentnih zahtjeva 1 - 4, naznačen time što je koncentracija bazne aminokiseline 1li njezinog derivata najmanje 1 mM i dovoljna je da spriječi ili smanji agregaciju enterovirusnih čestica i održava se tijekom cjelokupnog trajanja najmanje jednog od koraka b), c) i d).
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and at least one active agent, to form a composition; shaping said composition to form the extended release matrix formulation in the form of a tablet by direct compression; 
(1) barem jednog polietilen oksida koji ima, na osnovu reoloških mjerenja, prosječnu molekularnu težinu od barem 1,000,000, i (2) barem jednog aktivnog agensa, kako bi se formirao sastav; (b) oblikovanje navedenog sastava kako bi se formirala formulacija matrice s produljenim otpuštanjem u obliku tablete pomoću direktne kompresije;
The device of claim 4 wherein each of the link plates has opposite end portions extending radially outwardly beyond the respective rods when connected thereto of a length no greater than one-half the thickness of the strip sections. 
Uređaj u skladu s patentnim zahtjevom 4, naznačen time što svaka od spojnih ploča ima nasuprotne krajnje dijelove koji se pružaju radijalno prema van dulje od odgovarajućih štapova kada su spojeni s njima, duljine ne veće od polovine debljine dijelova vrpce.
Alternatively, the oral suspension may be mixed with foods or drinks. 
Alternativno, oralna suspenzija se može miješati sa hranom i pićem.
The rotary machine according to claim 1, wherein the rotor comprises two main parts, wherein the two main parts together form said reel structure configuration. 
Rotacijski motor prema patentnom zahtjevu 1, naznačen time da je rotor (2) napravljen od dva glavna dijela (2a, 2b) koji zajedno čine spomenutu valjkastu strukturnu konfiguraciju.
the provision of a second magnetic pole, its magnetic polarization opposite to the polarization of the first magnetic pole; the provision of a coil; 
pripremu drugog magnetskog pola (3a, 8a), čija je magnetska polarizacija suprotna magnetskoj polarizaciji prvog magnetskog pola (2b, 8b);
The compound for use according to claim 1 or 2 further comprising using one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of claim 1, or a pharmaceutically acceptable salt thereof or with the compound of claim 2. 
Spoj prema zahtjevu 42 koji dalje obuhvaća uporabu jednog ili dva dodatna spoja s djelovanjem protiv HCV-a prije, nakon ili istodobno sa spojem prema zahtjevu 1, ili njegovom farmaceutski prihvatljivom soli.
The organic phase was then dried on anhydrous sodium sulphate and evaporated. 
Organska faza je zatim osušena na bezvodnom natrij sulfatu i isparena.
is O or S, or N- R36 wherein R36 is H or C1-C3 alkyl; and Ar7 is a heterocyclyl, aryl or heteroaryl group, each of which being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, aryl or hydroxyl; and 
je O ili S, ili N-R36 gde R36 je H ili C1-C3alkil; i Ar7 je heterociklil, aril ili heteroaril skupina, pri tome je svaka izborno supstituirana s jednom ili više skupina odabranih od halo, cijano, alkil, haloalkil, ciklopropil, alkoksi, haloalkoksi, aril ili hidroksil; i
The compound of claim 1 which compound is 3-[5-amino-4-(3-iodo-benzoyl)-pyrazol-1-yl]N-cyclopropyl-4-methyl-benzamide, or a pharmaceutically acceptable salt thereof. 
Spoj formule I, naznačen time, da je to spoj 3-[5-amino-4-(3-cijanobenzoil)-pirazol-1-i1]-N-ciklopropil-4-metil-benzamid, ili njegov farmaceutski prihvatljiv derivat određen u zahtjevu 1, te da je za uporabu prema zahtjevu 1.
Generally the evacuation of a thermoblock serves to reduce scale deposition in the serpentines of the thermoblocks. 
Općenito, pražnjenje termobloka služi za smanjivanje taloženje kamenca u navojima termoblokova.
Preferably, the liquid is circulating in the device during step (ii). 
Poželjno je da tekućina cirkulira kroz opremu tijekom drugog koraka (11).
culturing the one or more cells in the copper supplemented cell culture media such that rVWF is expressed and excreted from the cells into a culture supernatant wherein the NH4+ content of the cell culture supernatant is maintained at a concentration below 4 mM; and 
provodi u perfuzijskom režimu. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što se jednu ili više stanica uzgaja u najmanje 100 l u nadopunjenom mediju za osnovnu kulturu stanica.
the solvent system comprises acetonitrile and methanol. 
(c) sustav otapala obuhvaća acetonitril i metanol.
at least 10% of the cells in the population express detectable levels of CD289 (Toll-like receptor 9), 
najmanje 10 % stanica u populaciji na svojoj površini izražava uočljive razine CD289 (receptor 9 tipa Toll),
the heavy chain variable domain is SEQ ID NO:83 and the light chain variable domain is SEQ ID NO:84; 
varijabilna domena jakog lanca je SEQ ID NO:55 i varijabilna domena slabog lanca je SEQ ID NO:56.
aryl, unsubstituted or mono- or bi-substituted independently with halogen. 
aril, nesupstituiran ili mono- ili bi-supstituiran neovisno s halogen.
a quantizer configured to perform quantization on a coding unit included in a current quantization group in a current thread which is a current parallel encodable data unit and a coding unit included in a next quantization group in a next thread which is a next parallel encodable data unit, wherein the current quantization group is a first quantization group in the current thread included in the slice, the next quantization group is a first quantization group in the next thread included in the slice, wherein each of the current thread and the next thread is among a plurality of threads included in the slice, wherein each of a plurality of threads including the current thread and the next thread is a plurality of largest coding blocks of the same row, 
WPP sadrži proces u kojem se informacija o vjerojatnosti za entropijsko dekodiranje prve najveće jedinice kodiranja za nit određuje korištenjem informacija o vjerojatnosti za entropijsko dekodiranje druge najveće jedinice kodiranja gornje niti, pri čemu se predviđeni QP kvantizacijske skupine, koja je u trenutnoj niti, i nije trenutna kvantizacijska skupina, generira pomoću kvantizacijskog parametra susjedne jedinice kodiranja kvantizacijske skupine u trenutnoj niti, pri čemu je svaka od trenutnih niti i sljedećih niti između mnoštva niti sadržana u odsječku, pri čemu je predviđeni QP prve kvantizacijske skupine u svakom od mnoštva niti početni QP na razini odsječka.
In certain embodiments, Xaa2 comprises a lower alkenoyl or lower alkyl substituent at the 1 position of tryptophan, Xaa3 optionally comprises a halogenated tryptophan and Xaa4 comprises Alanine. In particular embodiments, Xaa2 is 1-methyltryptophan or 1-formyltryptophan and Xaa3 optionally comprises 5-fluoro-1-tryptophan. 
Spoj prema zahtjevu 1, gdje Xaa2 je 1-metil triptofan, Xaa3 je po izboru analog od Trp gdje je vodik u indolu zamijenjen atomom fluora i Xaa4 je Ala. Spoj prema zahtjevu 6, gdje izborni Trp analog kao Xaa3 je 5-fluoro-1-triptofan.
A therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances. 
Terapijski djelotvornu količinu lako će odrediti nadležni dijagnostičar, kao stručna osoba, upotrebom uobičajenih tehnika, te iz rezultata opažanje dobivenih u analognim okolnostima.
at least one H3O+-ion provider having a pKa of less than or equal to 2.5, wherein the corresponding acid anion is capable of forming a water-soluble calcium salt, and at least one anion, provided in the form of a water-soluble salt or hydrogen salt, wherein the corresponding acid of this at least one anion has a pKa of less than or equal to 2.5 and wherein said anion is capable of forming water-insoluble calcium salts. 
Postupak prema bilo kojem od zahtjeva 1 do 16, naznačen time da je najmanje jedna kiselina koja ima pK, od manje od ili jednako 2.5 dana u obliku: najmanje jednog davatelja HgO'-iona koji ima pK, od manje od ili jednako 2.5, pri čemu je odgovarajući kiseli anion sposoban formirati kalcijevu sol koja je topiva u vodi, te najmanje jednog aniona, koji je pružen u obliku soli topive u vodi ili vodikove soli, pri čemu odgovarajuća kiselina toga najmanje jednog aniona ima pK, od manje od ili jednako 2.5 i pri čemu je navedeni anion sposoban formirati kalcijeve soli koje nisu topive u vodi.